FDA review doesn't find increased bleeding risk with dabigatran

03/14/2013 | Forbes

Fears over serious bleeding risk associated with dabigatran as compared with warfarin can be tied to the increased awareness and vigilance and "stimulated reporting" involving a new drug, FDA officials concluded in a perspective published in the New England Journal of Medicine. Researchers said that in reviewing data from the FDA Adverse Event Reporting System, they found "no indication that dabigatran was not being used in accordance with its labeled directions." The review also did not find increased bleeding risk with dabigatran compared with warfarin.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA